Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma

by S. L. George, V. Parmar, F. Lorenzi, L. V. Marshall, Y. Jamin, E. Poon, P. Angelini, L. Chesler
Published 2020-05-01

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

by J. Guan, E. R. Tucker, H. Wan, D. Chand, L. S. Danielson, K. Ruuth, A. El Wakil, B. Witek, Y. Jamin, G. Umapathy, S. P. Robinson, T. W. Johnson, T. Smeal, T. Martinsson, L. Chesler, R. H. Palmer, B. Hallberg
Published 2016-09-01